Angiogenesis Biomarkers Associated With Disease Progression in Lung Cancer
AssigneeRush University Medical Center
InventorJeffrey A. Borgia
Life of this patent
Estimating the term…
Abstract
Methods and kits are provided for determining lung cancer disease progression or for pathological stratification of solitary indeterminate nodules detected during lung cancer screening or for determining the likelihood of disease progression in a subject. The method includes obtaining a biological sample from the subject and assaying a level in the biological sample of a biomarker in a panel of biomarkers where the panel includes at least one biomarker. The method further includes comparing the biomarker level in the subject's sample to a cutoff value for each biomarker measured for the panel of biomarkers and determining whether the biomarker level is above or below the cutoff value.
Claims17
A method for determining lung cancer disease progression or for pathological stratification of solitary indeterminate nodules detected during lung cancer screening or for determining the likelihood of disease progression in a subject, the method comprising:
- obtaining a biological sample from the subject;
- assaying a level in the biological sample of a biomarker in a panel of biomarkers, the panel comprising at least one biomarker selected from the group consisting of Epidermal growth factor (EGF), Angiopoietin-2, granulocyte colony-stimulating factor (G-CSF), bone morphogenic protein 9 (BMP-9), Endoglin, Endothelin-1, Leptin, fibroblast growth factor-1 (FGF-1), FGF-2, Follistatin, interleukin-8 (IL-8), hepatocyte growth factor (HGF), heparin-binding epidermal growth factor (HB-EGF), placental growth factor (PLGF), vascular endothelial growth factor-A (VEGF-A), VEGF-C and VEGF-D;
- comparing the biomarker level in the subject's sample to a cutoff value for each biomarker measured for the panel of biomarkers;
- and
- determining whether the biomarker level is above or below the cutoff value.
Dependencies are inferred from the claim text.